Physician profile
Brian E Macy
NPI 1235542747
$2,219.33
in general payments reported to CMS, 2019-2025
20 companies · $672 in 2025
The $672 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $508 · 2023: $414 · 2024: $507 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $675.39 | 2021-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $240.14 | 2021-2025 | |
| Amgen INC. | $205.77 | 2021-2025 | Tavneos |
| Astrazeneca Pharmaceuticals Lp | $186.73 | 2022-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $137.37 | 2022-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $106.13 | 2021-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $99.03 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $82.40 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $71.15 | 2023-2024 | Purified Cortrophin Gel |
| Ardelyx, INC. | $69.04 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $63.35 | 2023-2025 | Benlysta, Jesduvroq, Arexvy |
| Ultragenyx Pharmaceutical INC. | $59.98 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $49.85 | 2025 | |
| Mallinckrodt Hospital Products INC. | $29.22 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.95 | 2023 | Oxlumo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.65 | 2022-2023 | Gattex |
| Opko Pharmaceuticals, LLC | $27.35 | 2022-2024 | Rayaldee |
| Lilly USA, LLC | $26.21 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $16.97 | 2023 | Strensiq |
| Merck Sharp & Dohme LLC | $16.65 | 2025 | Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Macy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.